Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) reached a new 52-week low during trading on Tuesday. The company traded as low as $4.05 and last traded at $4.38, with a volume of 6,417 shares traded. The stock had previously closed at $4.41.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings raised shares of Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday. One investment analyst has rated the stock with a Hold rating. According to data from MarketBeat, the stock has a consensus rating of “Hold”.
Get Our Latest Stock Report on NNNN
Anbio Biotechnology Stock Down 7.1%
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Further Reading
- Five stocks we like better than Anbio Biotechnology
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
- IonQ Fell 9% on a $1.3 Billion Deal—Is Wall Street Missing Something?
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
